» Articles » PMID: 1390330

Comparison of Captopril with Enalapril in the Treatment of Heart Failure: Influence on Hemodynamics and Measures of Renal Function

Overview
Date 1992 Apr 1
PMID 1390330
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Twenty-nine patients with severe heart failure (NYHA III) were randomly assigned to receive therapy with an angiotensin converting enzyme inhibitor (ACE inhibitor), either captopril or enalapril. The mean daily dosage of captopril was 56 +/- 5 mg and of enalapril 9.5 +/- 0.4 mg. After a mean of 8 +/- 1 days, the influence of both ACE inhibitors on hemodynamics and renal function was compared. The mean arterial pressure in the group treated with captopril (Group A) fell by 9 +/- 3 mmHg (p less than 0.01), and in the group treated with enalapril (Group B) it fell by 12 +/- 3 mmHg (p less than 0.001). The difference between the groups was not significant. Heart rate decreased in both groups; however, the change was significant (p less than 0.05) only in patients treated with enalapril (-11 +/- 3 bpm in Group B vs. -7 +/- 4 bpm in Group A). Stroke volume index increased by 6 +/- 3 ml/m2 in Group A (p less than 0.05) vs. 10 +/- 2 ml/m2 in Group B (p less than 0.01). The increase in stroke volume index was not significantly different between the two groups. Mean decreases in pulmonary artery and right atrial pressure were also comparable in both groups. Thus, hemodynamic improvements were similar during therapy with either captopril or enalapril. Serum sodium and potassium before therapy were 137 +/- 1 mmol/l and 4.1 +/- 0.1 mmol/l, respectively, in group A and 139 +/- 1 mmol/l and 4.0 +/- 0.1 mmol/l, respectively, in group B.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Identification of Bioactive Peptides from a Protein Hydrolysate Using In Silico and In Vitro Methods to Identify Angiotensin-1-Converting Enzyme (ACE-1) Inhibitory Peptides.

Purcell D, Packer M, Hayes M Mar Drugs. 2023; 21(2).

PMID: 36827131 PMC: 9967564. DOI: 10.3390/md21020090.


Angiotensin-I-Converting Enzyme Inhibitory Activity of Protein Hydrolysates Generated from the Macroalga (Hudson) JV Lamouroux 1813.

Purcell D, Packer M, Hayes M Foods. 2022; 11(12).

PMID: 35741988 PMC: 9222848. DOI: 10.3390/foods11121792.


Comparison of the Efficacy and Safety of Different ACE Inhibitors in Patients With Chronic Heart Failure: A PRISMA-Compliant Network Meta-Analysis.

Sun W, Zhang H, Guo J, Zhang X, Zhang L, Li C Medicine (Baltimore). 2016; 95(6):e2554.

PMID: 26871774 PMC: 4753869. DOI: 10.1097/MD.0000000000002554.


Dosing of ACE inhibitors in postinfarct protection.

Osterziel K, Dietz R Cardiovasc Drugs Ther. 1993; 7(6):881-3.

PMID: 8011563 DOI: 10.1007/BF00877719.


Choice of ACE inhibitor for congestive heart failure.

Opie L Cardiovasc Drugs Ther. 1992; 6(2):181.

PMID: 1390331 DOI: 10.1007/BF00054568.

References
1.
Packer M, Lee W, Medina N, Yushak M, Kessler P . Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med. 1987; 106(3):346-54. DOI: 10.7326/0003-4819-106-3-346. View

2.
Kjekshus J, Swedberg K . Enalapril for congestive heart failure. Am J Cardiol. 1989; 63(8):26D-32D. DOI: 10.1016/0002-9149(89)90414-1. View

3.
Powers E, Chiaramida A, DeMaria A, Giles T, Hackshaw B, Hart W . A double-blind comparison of lisinopril with captopril in patients with symptomatic congestive heart failure. J Cardiovasc Pharmacol. 1987; 9 Suppl 3:S82-8. DOI: 10.1097/00005344-198700003-00020. View

4.
Biollaz J, Burnier M, Turini G, Brunner D, Porchet M, Gomez H . Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther. 1981; 29(5):665-70. DOI: 10.1038/clpt.1981.92. View

5.
Semple P, Cumming A, MEREDITH P, Morton J . Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man. Cardiovasc Drugs Ther. 1987; 1(1):45-50. DOI: 10.1007/BF02125832. View